Prosecution Insights
Prosecution Insights
6 pending office actions • 3 art units • 5 examiners • 0 of 6 (0%) have an AI response strategy ready • 8 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (33%) |
| §102 only | 1 (17%) |
| §112 only | 2 (33%) |
| Double-patenting only | 1 (17%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LEESER, ERICH A | 2 | 81.6% | +13.5% |
| TAO, BIN | 1 | 100.0% | +0.0% |
| WELLS, LAUREN QUINLAN | 1 | 46.6% | +61.8% |
| KENYON, JOHN S | 1 | 80.2% | +17.5% |
| FETTEROLF, BRANDON J | 1 | 51.4% | +17.1% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18730769 | CRYSTAL FORM OF ALLYL-CONTAINING METHYLPYRIDOPYRIMIDINE COMPOUND | TAO, BIN | — |
| 18637382 | DEUTERATED NUCLEOSIDE COMPOUNDS AND USE THEREOF | LEESER, ERICH A | — |
| 18682091 | DEUTERATED NUCLEOSIDE COMPOUNDS AND USE THEREOF | LEESER, ERICH A | — |
| 18559968 | ALKYL CARBOXYLIC ACID COMPOUNDS AND APPLICATION THEREOF | KENYON, JOHN S | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18550468 | 6-CARBAMATE SUBSTITUTED HETEROARYL RING DERIVATIVES | FETTEROLF, BRANDON J | 16d overdue |
| 18637382 | DEUTERATED NUCLEOSIDE COMPOUNDS AND USE THEREOF | LEESER, ERICH A | — |
| 18688377 | HALOGEN-SUBSTITUTED PYRIDAZINONE COMPOUND AND APPLICATION THEREOF | WELLS, LAUREN QUINLAN | — |
| 18682091 | DEUTERATED NUCLEOSIDE COMPOUNDS AND USE THEREOF | LEESER, ERICH A | — |
| 18559968 | ALKYL CARBOXYLIC ACID COMPOUNDS AND APPLICATION THEREOF | KENYON, JOHN S | — |
| Art Unit | Apps |
|---|---|
| 1622 | 3 |
| 1625 | 1 |
| 1626 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18730769 | CRYSTAL FORM OF ALLYL-CONTAINING METHYLPYRIDOPYRIMIDINE COMPOUND | TAO, BIN | — | §102 | Non-Final OA | — | Pending | Jul 20, 2024 |
| 18637382 | DEUTERATED NUCLEOSIDE COMPOUNDS AND USE THEREOF | LEESER, ERICH A | 1622 | §112 | Non-Final OA | — | Pending | Apr 16, 2024 |
| 18688377 | HALOGEN-SUBSTITUTED PYRIDAZINONE COMPOUND AND APPLICATION THEREOF | WELLS, LAUREN QUINLAN | 1622 | §103 | Non-Final OA | — | Pending | Mar 01, 2024 |
| 18682091 | DEUTERATED NUCLEOSIDE COMPOUNDS AND USE THEREOF | LEESER, ERICH A | 1622 | §103 | Non-Final OA | — | Pending | Feb 07, 2024 |
| 18559968 | ALKYL CARBOXYLIC ACID COMPOUNDS AND APPLICATION THEREOF | KENYON, JOHN S | 1625 | DP | Non-Final OA | — | Pending | Nov 09, 2023 |
| 18550468 | 6-CARBAMATE SUBSTITUTED HETEROARYL RING DERIVATIVES | FETTEROLF, BRANDON J | 1626 | §112 | Non-Final OA | 16d overdue | Pending | Sep 14, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial